MHRA Says UK Approach To AI Regulation ‘Legislatively Light’, Unlike EU Proposals
The UK’s medtech regulator is “going big on guidance” when it comes to artificial intelligence and software as a medical device, an expert from the agency has said, while legislation will be light in comparison to the EU’s planned AI Act.
You may also be interested in...
The UK government says that its non-legislative approach to AI regulation will promote innovation and allow it to react quickly to changes in the ecosystem. But a life sciences lawyer warns that creating an uncertain regulatory environment could be problematic.
Nuray Yurt, Merck’s business engagement and activation lead for digital data and analytics, told In Vivo about her hopes for the future of AI regulation and how stakeholders ought to reframe their understanding of the sector.
The UK government has proposed a “pro-innovation” AI regulation strategy, which will utilize the expertise of existing regulators and avoid new legislation. But what does this mean for the medtech sector, and how does the UK approach differ from the EU’s AI Act?